Navigation Links
VIVUS Announces Sale of MUSE Assets to Meda
Date:10/4/2010

MOUNTAIN VIEW, Calif., Oct. 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it has entered into an asset purchase agreement with Meda - an international specialty pharma company - for MUSE®, transurethral alprostadil, for the treatment of erectile dysfunction (ED).  Under the agreement, Meda will acquire the MUSE assets including the United States and foreign MUSE patents, existing inventory and the manufacturing facility located in Lakewood, New Jersey.  As part of the transaction, the existing VIVUS employees that are MUSE dedicated, including the field sales force, are expected to join Meda. VIVUS will retain all of the liabilities associated with the pre-closing operations of the MUSE business.

"We have been business partners with Meda in Europe for MUSE since 2000 and the acquisition of MUSE fits with their expansion plans," stated Leland Wilson, chief executive officer of VIVUS.  "The divestiture of MUSE to Meda will allow us to focus on our commercialization efforts for QNEXA for obesity and development of avanafil for erectile dysfunction.  I appreciate all the efforts from those employees that have been involved with MUSE since its approval in late 1996.  As part of the Meda urology portfolio, we expect MUSE to continue to meet the needs of ED patients and their providers for years to come."

The acquisition price is $23.5 million, which includes an upfront cash payment of $22 million.  VIVUS is eligible to receive a one-time milestone payment of $1.5 million based on future sales of MUSE.  The transaction is subject to standard closing requirements and conditions.  The transaction is expected to close on or before November 15, 2010.

About MUSEIn 1997, VIVUS commercially launched MUSE in the United States. MUSE was the first minimally invasive therapy for erectile dysfunction approved by the FDA. With MUSE, an erection is typically produced within 15 minutes of administration and lasts approximately 30 to 60 minutes. Alprostadil is the active pharmacologic agent used in MUSE. Alprostadil is the generic name for the synthetic version of prostaglandin E1, a naturally-occurring vasodilator present in the human body and at high levels in seminal fluid.

MUSE is designed to overcome the limitations of other available therapies through its unique product attributes. Because therapeutic levels of drug are delivered locally to the erectile tissues with minimal systemic drug exposure, MUSE is a relatively safe, local treatment that minimizes the chances of systemic interactions with other drugs or diseases. Because it mimics the normal vasoactive process, MUSE produces an erection that is more natural than those resulting from needle injection therapy, vacuum constriction devices or penile implants.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2009 and periodic reports filed with the Securities and Exchange Commission.CONTACT:VIVUS, Inc.Investor Relations:Timothy E. MorrisThe Trout GroupChief Financial Officer

Brian Korb650-934-5200

646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
2. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
3. VIVUS to Present at Lazard Capital Markets Healthcare Conference
4. VIVUS Announces Promotion of Peter Tam to President
5. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
6. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
7. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
8. NCPA Announces New Division Dedicated to Long-Term Care Pharmacies, Patients
9. Concentric Medical Announces Product and Procedure Reimbursement as Well as Full Commercialization of the Merci Retriever® in Japan
10. Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
11. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... Growth and Demand Forecast to 2022" report to their offering. ... The global wound care market ... at a CAGR of 6.7% during 2016-2022 Among the various ... largest share in the global market in 2015. Among the various applications, ...
(Date:3/24/2017)... -- FinancialBuzz.com News Commentary  ... According to new data published ... the legal cannabis market is projected to continue to grow ... from the current presidential administration. The report created by Arcview,s ... of growth in this industry are the passage and subsequent ...
(Date:3/24/2017)... -- Global Ampoules Market report provides a ... and industry chain structure. The Ampoules market analysis is ... landscape analysis, and major regions, development status. ... Complete ... 10 company profiles and 183 tables and figures is ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro Health ... to prep patients for colonoscopy at the HyGIeaCare® Center that is to be ... FL. , The HyGIeaCare® Prep, cleared by the U.S. Food and ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... with God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true communion ... to Walk with God #TruthwithGrace” is the creation of published author Lea Michelle ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of Saints: A ... God in congregations across the United States. “The Communion of Saints” is ... who has served congregations in seven states throughout his long career of devotion ...
(Date:3/23/2017)... ... , ... A recent report from the National Council on Teacher Quality (NCTQ) ... suggests, based on a review of GPA and SAT/ACT requirements at 221 institutions in ... It argues that this higher bar should be set by states, by the Council ...
(Date:3/23/2017)... TX (PRWEB) , ... March 23, 2017 , ... ... clinic, located at 960 Gruene Road in Building 2. The clinic is the group’s ... Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things full ...
Breaking Medicine News(10 mins):